2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
CAS NO.：1001753-24-7 Product Name：N-[4-(2,4,6-trimethylphenyl)-1,3-thiazol-2-yl]benzamide Synonyms：N-(4-mesitylthiazol-2-yl)benzamide;INH6;N-[4-(2,4,6-trimethylphenyl)thiazol-2-yl]benzamide;N-[4-(2,4,6-trimethylphenyl)-2-thiazolyl]-benzamide;N-[4-(2,4,6-trimethylphenyl)-1,3-thiazol-2-yl]benzamide;C19H18N2OS;N-(4-(2,4,6-trimethylphenyl)thiazol-2-yl)benzamide;AMBZ0346;HMS3653H09;BCP11030;BQB75324;2569AH;s7494;AM85436 EINEC: Molecular Formula：C19H18N2OS Molecular Weight：322.4240
Target:
In Vivo
In Vitro
Hec1 is an oncogene overly expressed in many human cancers. Small molecule INH (Inhibitor of Nek2/Hec1) targeting the Hec1 and its regulator, Nek2, in the mitotic pathway is identified to inactivate Hec1/Nek2 function mediated by protein degradation that subsequently leads to chromosome mis-segregation and cell death. INH6 treated cells exhibit increased mitotic population with multipolar spindle configurations. An increased rate of chromosome misalignment is detected upon treatment with INH6 of HeLa cells expressing the chromosome marker protein H2B-GFP. INH6 treated cells shows progressive morphological changes characteristic of dying cells (e.g., membrane bubbling), which is further confirmed by cell cycle profiling with FACS analysis. Approximately 20% of INH6 treated cells are apoptotic 72 hrs after treatment[1].
Kinase Assay
Cell Assay
Standard XTT assays with a four-day drug treatment procedure were performed to measure the dose-dependent cytotoxicity of INH analogs in cultured cells. Triplicate sets were measured and compiled for final data presentation. Cells were plated on 96-well dishes one day before the drug treatment, followed by drug treatment (2.5 μM INH6) on day 2 and XTT assay on day 5 after drug addition. The absorption at 595 nm was measured with a plate reader and converted to cell survival percentages in comparison to mock treated groups[1].
Animal Administration
References
[1]. Qiu XL, et al. Synthesis and biological evaluation of a series of novel inhibitor of Nek2/Hec1 analogues. J Med Chem. 2009 Mar 26;52(6):1757-67.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
